GlassScriptPhysician profile
Luis F Arango
NPI 1407877046
$4,962.21
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,346 · 2020: $1,382 · 2021: $1,291 · 2022: $516 · 2023: $268 · 2024: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $764.18 | 2019-2024 | Farxiga |
| Pfizer INC. | $743.93 | 2019-2024 | |
| Lilly USA, LLC | $556.84 | 2019-2023 | Trulicity, Mounjaro |
| Novo Nordisk INC | $504.93 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $431.98 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $330.36 | 2020-2022 | |
| Radius Health, INC. | $210.18 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.14 | 2019-2022 | |
| Astellas Pharma US INC | $162.50 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $152.67 | 2019-2022 | |
| Redhill Biopharma INC. | $125.98 | 2020-2023 | Talicia |
| Amarin Pharma, INC. | $115.64 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $75.24 | 2019-2023 | Spravato |
| Electromed, INC. | $74.28 | 2021-2023 | Smartvest |
| Mylan Specialty L.P. | $60.42 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $58.92 | 2019 | |
| Amgen INC. | $55.52 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $48.22 | 2019-2022 | |
| Cook Medical LLC | $39.03 | 2021 | |
| Biogen, INC. | $34.61 | 2021 | |
| Si-Bone, INC. | $31.01 | 2021-2022 | |
| Philips North America LLC | $29.59 | 2023-2024 | (O58) Sleep Respiratory Care Und |
| Allergan, INC. | $28.04 | 2020 | |
| Sumitomo Pharma America, INC. | $25.79 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.06 | 2021 | |
| Eisai INC. | $25.00 | 2024 | |
| Corcept Therapeutics | $24.43 | 2024 | Korlym |
| Advanced Respiratory, INC | $21.79 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.89 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $17.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Arango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.